Want to join the conversation?
$DCI, which competes with rivals $MFRI and $CMI, said its engine segment ended little short of forecast while industrial was little ahead for 3Q16. In aggregate, the company said, the business is showing more signs of stability. In the quarter, $DCI also said that more than 60% of its revenue came from replacement parts.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.